NCT06622070PHASE1RecruitingAccepts Healthy Volunteers
A Study of SPY002-072 in Healthy Volunteers
Spyre Therapeutics, Inc.
Start Date
11/18/2024
Completion Date
8/8/2026
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single-dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-072 in healthy participants.
Eligibility Criteria
Age Range: 18 years to 60 years
Inclusion Criteria:
* Healthy men and women
* Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits
Exclusion Criteria:
* Participation in more than one cohort
* Evidence of clinically significant abnormality or disease
* Known history of illicit drug use or drug abuse, cannabis/cannabinoid use, harmful alcohol use (at the Investigator's discretion), alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study agent
* History of severe allergic reactions or hypersensitivity
* Donation or loss of ≥ 1 unit of whole blood within 1 month prior to dosing
Interventions
DRUG
SPY002-072
OTHER
Placebo
Conditions
Healthy
Locations
Spyre Site 2
Cypress, California 90630
United States
Spyre Site 1
Montreal, Quebec H3P 3P1
Canada